Satellos Bioscience Inc. (TSX:MSCL)
Canada
· Delayed Price · Currency is CAD 15.89
-0.31 (-1.91%)
Mar 9, 2026, 1:25 PM EST
Satellos Bioscience Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Net Income | -21.57 | -19.53 | -12.03 | -8.37 | -12.25 | -1.24 | Upgrade
|
| Depreciation & Amortization | 0.01 | 0.01 | 0.01 | 0.25 | 0.13 | 0 | Upgrade
|
| Asset Writedown & Restructuring Costs | -0.09 | 2.72 | - | 2.13 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 0.03 | 0.03 | - | -0.03 | - | - | Upgrade
|
| Stock-Based Compensation | 2.53 | 1.47 | 1.64 | 1.06 | 0.77 | 0.07 | Upgrade
|
| Other Operating Activities | -0.69 | -1.35 | 1.33 | 0.05 | 7.76 | 0.01 | Upgrade
|
| Change in Accounts Receivable | - | - | - | - | 0.03 | -0.02 | Upgrade
|
| Change in Accounts Payable | 0.93 | 0.96 | 0.6 | 0.54 | -0.31 | -0.35 | Upgrade
|
| Change in Other Net Operating Assets | -2.38 | -1.67 | -0.32 | 0.2 | -0.11 | 0.23 | Upgrade
|
| Operating Cash Flow | -21.23 | -17.36 | -8.77 | -4.17 | -3.98 | -1.3 | Upgrade
|
| Capital Expenditures | -0.01 | -0 | -0.01 | -0 | -0.01 | - | Upgrade
|
| Cash Acquisitions | - | - | - | - | 1.38 | - | Upgrade
|
| Investment in Securities | -15.9 | 4.41 | -13.27 | - | - | - | Upgrade
|
| Investing Cash Flow | -15.9 | 4.4 | -13.28 | -0 | 1.37 | - | Upgrade
|
| Short-Term Debt Issued | - | - | 1.81 | - | - | - | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | 0.15 | 0.85 | Upgrade
|
| Total Debt Issued | - | - | 1.81 | - | 0.15 | 0.85 | Upgrade
|
| Short-Term Debt Repaid | - | - | -1.99 | - | - | - | Upgrade
|
| Total Debt Repaid | - | - | -1.99 | - | - | - | Upgrade
|
| Net Debt Issued (Repaid) | - | - | -0.18 | - | 0.15 | 0.85 | Upgrade
|
| Issuance of Common Stock | 33.24 | 30.33 | 26.62 | 1.47 | 5.74 | 0.7 | Upgrade
|
| Other Financing Activities | 7.07 | 6.85 | 11.74 | 0.58 | - | - | Upgrade
|
| Financing Cash Flow | 40.31 | 37.17 | 38.19 | 2.05 | 5.89 | 1.55 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.92 | 0.52 | -0.88 | -0.06 | -0 | - | Upgrade
|
| Net Cash Flow | 4.1 | 24.74 | 15.25 | -2.18 | 3.28 | 0.25 | Upgrade
|
| Free Cash Flow | -21.23 | -17.36 | -8.79 | -4.17 | -3.98 | -1.3 | Upgrade
|
| Free Cash Flow Per Share | -1.60 | -1.81 | -1.22 | -1.40 | -1.99 | -0.88 | Upgrade
|
| Levered Free Cash Flow | -13.99 | -11.22 | -5.49 | -1.85 | -0.13 | -0.87 | Upgrade
|
| Unlevered Free Cash Flow | -13.99 | -11.22 | -5.41 | -1.85 | -0.1 | -0.86 | Upgrade
|
| Change in Working Capital | -1.45 | -0.71 | 0.28 | 0.73 | -0.38 | -0.14 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.